Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
- Authors
- Kreisler, Alexandre; Duhamel, Alain; Vanbesien-Mailliot, Christel; DestΓ©e, Alain; Bordet, RΓ©gis
- Year
- 2010
- Journal
- Behavioural pharmacology
- PMID
- 20440202
- DOI
- 10.1097/FBP.0b013e32833a5c81
Earlier study from our group indicated that the peroxisome proliferator-activated receptor-alpha agonist fenofibrate prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic cell loss in C57Bl/6 mice. Our objective was to determine whether or not fibratescan improve motor activity in two experimental models of Parkinson's disease: the MPTP C57Bl/6 mouse and the 6-hydroxydopamine (6-OHDA) Wistar rat. Six groups of mice were set up: sham, sham-fenofibrate, sham-bezafibrate, MPTP, MPTP-fenofibrate and MPTP-bezafibrate. Mice were fed a diet containing 0.2% fenofibrate, 0.2% bezafibrate or no hypolipidaemic agent for 2 weeks. Four groups of rats were set up: sham, sham-fenofibrate, 6-OHDA and 6-OHDA-fenofibrate. Rats were fed a diet containing 0.2% fenofibrate or no hypolipidaemic agent for 4 weeks. In mice, motor activity was quantified using actimetry. Nine parameters were recorded. The results were analyzed with a mixed linear model. In rats, behavioural sensitization was studied with repetitive injections of apomorphine. All the actimetry parameters indicated a decrease of locomotion the day after MPTP injections and eight parameters improved in MPTP mice treated with fenofibrate or bezafibrate. The apomorphine-induced rotation behaviour mildly decreased in 6-OHDA rats treated with fenofibrate, but behavioural sensitization was unchanged. The 6-OHDA and MPTP compounds have different toxicity mechanisms, which could explain why we did not observe the same effect in 6-OHDA rats as in MPTP mice. These data suggest that the protective effect of fibrates can be carried through inhibition of inflammation rather than oxidative stress.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | 2015 | 25516156 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson's disease. | Qin B et al. | β | 2025 | β |
| Proliferator-Activated Receptor Alpha Inhibits Abnormal Extracellular Matrix Accumulation and Maintains Energy Metabolism in Late-Onset Fuchs Endothelial Corneal Dystrophy. | Li X et al. | β | 2025 | β |
| Bezafibrate attenuates immobilization-induced muscle atrophy in mice. | Nakamura S et al. | β | 2024 | β |
| Bezafibrate confers neuroprotection in the 5xFAD mouse model of Alzheimer's disease. | Lu Y et al. | β | 2023 | β |
| The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders. | Matrisciano F et al. | β | 2023 | β |
| Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration. | Durai P et al. | β | 2022 | β |
| Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson's disease. | Barbiero JK et al. | β | 2022 | β |
| A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice. | Caillaud M et al. | β | 2020 | β |
| Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases. | Assaf N et al. | β | 2020 | β |
| Bezafibrate In Vivo Administration Prevents 3-Methylglutaric Acid-Induced Impairment of Redox Status, Mitochondrial Biogenesis, and Neural Injury in Brain of Developing Rats. | da Rosa-Junior NT et al. | β | 2019 | β |
| Brilliant Blue G, But Not Fenofibrate, Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinson's Disease. | Ferrazoli EG et al. | β | 2017 | β |
| Allogeneic/xenogeneic transplantation of peptide-labeled mitochondria in Parkinson's disease: restoration of mitochondria functions and attenuation of 6-hydroxydopamine-induced neurotoxicity. | Chang JC et al. | β | 2016 | β |
| Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. | Zeissler ML et al. | β | 2016 | β |
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | β | 2015 | β |
| Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. | Barbiero JK et al. | β | 2014 | β |
| PPAR-Ξ± agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease. | Barbiero JK et al. | β | 2014 | β |
| Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. | Dumont M et al. | β | 2012 | β |
| Differential susceptibility to the PPAR-Ξ³ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. | Laloux C et al. | β | 2012 | β |
| Neuroprotective strategies involving ROS in Alzheimer disease. | Dumont M et al. | β | 2011 | β |